pharmaphorum August 2, 2024
Eli Lilly’s dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.
The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved to reduce the risk of serious cardiovascular conditions in people who are overweight or obese and showed a benefit in heart failure in a late-stage trial reported last year.
Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound...
Today's Sponsors
Today's Sponsor